OLMA Form 144: Proposed Sale of 13,086 Shares (~$109K)
Olema Pharmaceuticals (OLMA) filed a Form 144 proposing the sale of 13,086 common shares.
Rhea-AI Filing Summary
Olema Pharmaceuticals (OLMA) filed a Form 144 proposing the sale of 13,086 common shares. The sale is to be executed through Fidelity Brokerage Services with an approximate aggregate market value of $108,977.56 and an intended sale date of 09/18/2025. The company reports 68,634,329 shares outstanding, making the proposed sale a small portion of outstanding stock. The filer acquired 10,000 shares as founders shares on 03/20/2007 (compensation) and 3,086 shares in an open-market purchase on 06/30/2014 (cash). The filing also discloses recent sales on 09/16/2025: 10,000 shares by Cyrus L. Harmon for $80,362.60 and 1,914 shares by Harmon Family Investors LLC for $15,464.28. The filer certifies no undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider sale is immaterial relative to outstanding shares and unlikely to move valuation.
The Form 144 notifies the market of a proposed sale of 13,086 common shares valued at about $109k against 68.6 million shares outstanding, representing roughly 0.019% of the float. The filing documents the original acquisition dates and payment methods, clarifying these are not recent compensatory grants except for long-held founder shares. Recent reported sales on 09/16/2025 provide execution context. From a capital-markets perspective, the size and timing indicate routine disposition rather than a material corporate development.
TL;DR: Disclosure meets Rule 144 requirements; no governance red flags evident in the form.
The notice includes required details: broker, number of shares, aggregate value, acquisition history, and prior sales in the three-month lookback. The signer affirms absence of undisclosed material information and references compliance with trading-plan language. There are no indications of unusual selling patterns or related-party complications in the provided data. This filing appears to be a routine insider sale disclosure under securities rules.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 for OLMA disclose about the proposed sale?
Were there any sales of OLMA securities in the past three months disclosed?
Does the filer state there is any undisclosed material information?
AI-generated analysis. How Rhea-AI works. Not financial advice.